FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794321753> ?p ?o ?g. }

• W2794321753 endingPage "897" @default.
• W2794321753 startingPage "889" @default.
• W2794321753 abstract "Rationale and Objectives The objective of this study was to investigate the contrast-enhanced ultrasound (CEUS) characteristics of tumor angiogenesis in mouse mammary cancer. Materials and Methods Twenty-four mice were examined with ultrasound and CEUS at 2–12 days after implantation. Four to five mice were assessed daily, and one to three mice were then sacrificed for histology. All of the histologic slides were reviewed and correlated with CEUS findings. Results A total of 46 cases of ultrasound examination had been performed in 24 mice. The mice were classified into three groups according to the tumor growth: group 1 (2~6 days after implantation, n = 20 cases), group 2 (7~9 days after implantation, n = 15 cases), and group 3 (10~12 days after implantation, n = 11 cases). In group 1, all tumors presented as a homogeneous hypoechoic mass with no color Doppler signals. However, three CEUS patterns were observed: 14 tumors presented as type I (peripheral ring enhancement with no enhancement within the tumor), 4 tumors presented as type II (peripheral ring enhancement with deep penetration), and 2 tumors presented as type III (homogeneous or heterogeneous enhancement in the entire tumor). In group 2, there was only difference in the echo (heterogeneous or not) and color Doppler signals (with or without) among the tumors in conventional ultrasound, but four CEUS patterns were observed and most presented as type III (53.3%, 8/15). In group 3, most tumors presented as a heterogeneous solid mass (81.8%, 9/11) with color signals (100%, 11/11), and almost all tumors presented as enhancement of type IV (peripheral ring enhancement with focal nodular enhancement) (90.9%, 10/11).The histologic results showed that the enhanced areas mainly corresponded to tumor cells, large tortuous vessels, and an inflammatory cell infiltrate. Nonenhanced areas corresponded to large areas of necrotic tissue or tumor cells, which arranged loosely with the small zone of necrosis. Conclusions CEUS could image the progression of vessel formation. Moreover, most importantly, CEUS is able to identify angiogenesis before the change of tumor color Doppler, and presents different enhanced patterns at different tumor growth times, which corresponded to tumor histologic features. The objective of this study was to investigate the contrast-enhanced ultrasound (CEUS) characteristics of tumor angiogenesis in mouse mammary cancer. Twenty-four mice were examined with ultrasound and CEUS at 2–12 days after implantation. Four to five mice were assessed daily, and one to three mice were then sacrificed for histology. All of the histologic slides were reviewed and correlated with CEUS findings. A total of 46 cases of ultrasound examination had been performed in 24 mice. The mice were classified into three groups according to the tumor growth: group 1 (2~6 days after implantation, n = 20 cases), group 2 (7~9 days after implantation, n = 15 cases), and group 3 (10~12 days after implantation, n = 11 cases). In group 1, all tumors presented as a homogeneous hypoechoic mass with no color Doppler signals. However, three CEUS patterns were observed: 14 tumors presented as type I (peripheral ring enhancement with no enhancement within the tumor), 4 tumors presented as type II (peripheral ring enhancement with deep penetration), and 2 tumors presented as type III (homogeneous or heterogeneous enhancement in the entire tumor). In group 2, there was only difference in the echo (heterogeneous or not) and color Doppler signals (with or without) among the tumors in conventional ultrasound, but four CEUS patterns were observed and most presented as type III (53.3%, 8/15). In group 3, most tumors presented as a heterogeneous solid mass (81.8%, 9/11) with color signals (100%, 11/11), and almost all tumors presented as enhancement of type IV (peripheral ring enhancement with focal nodular enhancement) (90.9%, 10/11).The histologic results showed that the enhanced areas mainly corresponded to tumor cells, large tortuous vessels, and an inflammatory cell infiltrate. Nonenhanced areas corresponded to large areas of necrotic tissue or tumor cells, which arranged loosely with the small zone of necrosis. CEUS could image the progression of vessel formation. Moreover, most importantly, CEUS is able to identify angiogenesis before the change of tumor color Doppler, and presents different enhanced patterns at different tumor growth times, which corresponded to tumor histologic features." @default.
• W2794321753 created "2018-03-29" @default.
• W2794321753 creator A5018245913 @default.
• W2794321753 creator A5021020705 @default.
• W2794321753 creator A5030538673 @default.
• W2794321753 creator A5044072965 @default.
• W2794321753 creator A5063632964 @default.
• W2794321753 creator A5071389166 @default.
• W2794321753 creator A5077128786 @default.
• W2794321753 creator A5084445575 @default.
• W2794321753 date "2018-07-01" @default.
• W2794321753 modified "2023-10-16" @default.
• W2794321753 title "Angiogenesis Research in Mouse Mammary Cancer Based on Contrast-enhanced Ultrasonography" @default.
• W2794321753 cites W1591934633 @default.
• W2794321753 cites W1884247889 @default.
• W2794321753 cites W1971505722 @default.
• W2794321753 cites W1996008910 @default.
• W2794321753 cites W2006870848 @default.
• W2794321753 cites W2008485376 @default.
• W2794321753 cites W2009240587 @default.
• W2794321753 cites W2053028241 @default.
• W2794321753 cites W2064295482 @default.
• W2794321753 cites W2070276211 @default.
• W2794321753 cites W2072928113 @default.
• W2794321753 cites W2087428579 @default.
• W2794321753 cites W2100710504 @default.
• W2794321753 cites W2104712200 @default.
• W2794321753 cites W2111925159 @default.
• W2794321753 cites W2122789466 @default.
• W2794321753 cites W2122991294 @default.
• W2794321753 cites W2147277247 @default.
• W2794321753 cites W2158503340 @default.
• W2794321753 cites W2508664280 @default.
• W2794321753 doi "https://doi.org/10.1016/j.acra.2017.12.004" @default.
• W2794321753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29398438" @default.
• W2794321753 hasPublicationYear "2018" @default.
• W2794321753 type Work @default.
• W2794321753 sameAs 2794321753 @default.
• W2794321753 citedByCount "5" @default.
• W2794321753 countsByYear W27943217532019 @default.
• W2794321753 countsByYear W27943217532020 @default.
• W2794321753 countsByYear W27943217532023 @default.
• W2794321753 crossrefType "journal-article" @default.
• W2794321753 hasAuthorship W2794321753A5018245913 @default.
• W2794321753 hasAuthorship W2794321753A5021020705 @default.
• W2794321753 hasAuthorship W2794321753A5030538673 @default.
• W2794321753 hasAuthorship W2794321753A5044072965 @default.
• W2794321753 hasAuthorship W2794321753A5063632964 @default.
• W2794321753 hasAuthorship W2794321753A5071389166 @default.
• W2794321753 hasAuthorship W2794321753A5077128786 @default.
• W2794321753 hasAuthorship W2794321753A5084445575 @default.
• W2794321753 hasConcept C121332964 @default.
• W2794321753 hasConcept C126322002 @default.
• W2794321753 hasConcept C126838900 @default.
• W2794321753 hasConcept C142724271 @default.
• W2794321753 hasConcept C143753070 @default.
• W2794321753 hasConcept C2779585989 @default.
• W2794321753 hasConcept C2780394083 @default.
• W2794321753 hasConcept C2989005 @default.
• W2794321753 hasConcept C3019130837 @default.
• W2794321753 hasConcept C46762472 @default.
• W2794321753 hasConcept C529618451 @default.
• W2794321753 hasConcept C57742111 @default.
• W2794321753 hasConcept C66882249 @default.
• W2794321753 hasConcept C71924100 @default.
• W2794321753 hasConcept C97355855 @default.
• W2794321753 hasConceptScore W2794321753C121332964 @default.
• W2794321753 hasConceptScore W2794321753C126322002 @default.
• W2794321753 hasConceptScore W2794321753C126838900 @default.
• W2794321753 hasConceptScore W2794321753C142724271 @default.
• W2794321753 hasConceptScore W2794321753C143753070 @default.
• W2794321753 hasConceptScore W2794321753C2779585989 @default.
• W2794321753 hasConceptScore W2794321753C2780394083 @default.
• W2794321753 hasConceptScore W2794321753C2989005 @default.
• W2794321753 hasConceptScore W2794321753C3019130837 @default.
• W2794321753 hasConceptScore W2794321753C46762472 @default.
• W2794321753 hasConceptScore W2794321753C529618451 @default.
• W2794321753 hasConceptScore W2794321753C57742111 @default.
• W2794321753 hasConceptScore W2794321753C66882249 @default.
• W2794321753 hasConceptScore W2794321753C71924100 @default.
• W2794321753 hasConceptScore W2794321753C97355855 @default.
• W2794321753 hasFunder F4320321001 @default.
• W2794321753 hasIssue "7" @default.
• W2794321753 hasLocation W27943217531 @default.
• W2794321753 hasLocation W27943217532 @default.
• W2794321753 hasOpenAccess W2794321753 @default.
• W2794321753 hasPrimaryLocation W27943217531 @default.
• W2794321753 hasRelatedWork W2276392809 @default.
• W2794321753 hasRelatedWork W2373176402 @default.
• W2794321753 hasRelatedWork W2374744847 @default.
• W2794321753 hasRelatedWork W2380303152 @default.
• W2794321753 hasRelatedWork W2392940771 @default.
• W2794321753 hasRelatedWork W2795533457 @default.
• W2794321753 hasRelatedWork W2917289341 @default.
• W2794321753 hasRelatedWork W2979003513 @default.
• W2794321753 hasRelatedWork W3030454440 @default.
• W2794321753 hasRelatedWork W4304175601 @default.
• W2794321753 hasVolume "25" @default.

• next